US Markets

Regeneron says its COVID-19 antibody treatment cut medical visits in trial

Credit: REUTERS/BRENDAN MCDERMID

Regeneron Pharmaceuticals Inc said on Wednesday that its COVID-19 antibody cocktail - the experimental treatment that U.S. President Donald Trump received - significantly reduced medical visits in a trial of more than 500 patients with mild-to-moderate sickness.

Corrects trial size

Oct 28 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O said on Wednesday that its COVID-19 antibody cocktail - the experimental treatment that U.S. President Donald Trump received - significantly reduced medical visits in a trial of around 800 patients with mild-to-moderate sickness.

The company said it has shared the results with the U.S. Food and Drug Administration as part of its review of the company's request for emergency use authorization of the treatment.

(Reporting by Michael Erman; Editing by Leslie Adler)

((michael.erman@thomsonreuters.com; +1 646-223-6021; Reuters Messaging: michael.erman.thomsonreuters.com@thomsonreuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

REGN

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More